September 30, 2019
Video
David S. Hong, MD, discusses updated data with larotrectinib (Vitrakvi) in TRK fusion-positive solid tumors at the ESMO Congress 2019.
April 25, 2019
Video
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
April 01, 2019
Video
David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.